Psychiatry

Psychiatrists at the 2025 So Cal Psych Conference shared evidence-based tools and therapies to improve mental health outcomes for new mothers.

In this Q&A, Alva discusses how to identify tardive dyskinesia, approaches for treatment-resistant depression, and emerging therapies.

At 2025 So Cal Psych, Maguire shared insights on diagnosing bipolar depression, treating agitation in dementia, and managing mental health challenges in patients who stutter.

Patients who adhered to a strict 12-week low FODMAP diet saw improvements in fatigue, anxiety, and depression, and performed better on an attention test.

At So Cal Psych 2025, Monroe discusses the promise of xanomeline-trospium (Cobenfy) and its novel mechanism.

Discover the latest insights on tardive dyskinesia treatment, diagnosis, and the role of VMAT2 inhibitors in enhancing patient well-being.

An audio recap of the top 5 stories in healthcare news from the week of 06/30-07/06.

Stay updated with the latest healthcare breakthroughs, including FDA news, clinical trial data, and regulatory submissions, in this week's essential news roundup.

Discover cutting-edge insights on schizophrenia, mood disorders, and digital therapeutics at the 2025 Southern California Psychiatry Conference.

Shaker shares how allergist-immunologists can use brief CBT, motivational interviewing, and risk reframing to shift patients’ fear of their food allergies into confidence.

Explore the transformative potential of MDMA-assisted therapy and psychedelics in treating PTSD and addiction, offering hope where traditional methods fail.

Transcend Therapeutics' TSND-201 gains FDA Breakthrough Therapy designation, offering new hope for rapid PTSD treatment with promising clinical trial results.

Discover how structured routines and exercise enhance mental health for those with bipolar disorder, fostering stability, and community support.

Johnson & Johnson seeks FDA approval for lumateperone (CAPLYTA) to significantly reduce schizophrenia relapse risk. Company submits an sNDA.

Long-acting injectables improve outcomes in schizophrenia, yet remain underutilized, highlighting the need for earlier, proactive conversations in care.

5 FDA updates in psychiatry from the first half of 2025, plus other pipeline developments in psychiatry for depression, schizophrenia, and OUD.

This Q2 psychiatry recaps promising data of COMP360 for treatment-resistant depression, the expansion of clozapine access, and experts weighing in on new data and ethical debates.

At SDPA 2025, Theodore Rosen, MD, discussed various psychological disorders, including delusions of parasitosis, excoriation disorder, dermatitis artefacta, and others.

A single 25 mg dose of synthetic psilocybin led to a significant reduction in depression severity at 6 weeks in the pivotal COMP005 trial for TRD, meeting its primary endpoint.

In this episode of The Gus Alva Perspective, Gus Alva sits down with Roger McIntyre to discuss his highly anticipated keynote address, titled "The Intersection of Metabolism and Mood”, from the upcoming 2025 Southern California Psychiatry Conference.

Jonathan Meyer, MD, previews his session on updates in tardive dyskinesia at the upcoming 2025 Southern California Psychiatry Conference.

At SLEEP 2025, Colvonen discussed RCT findings that showed VeNS significantly improved PTSD and insomnia symptoms, offering a scalable solution for patients awaiting 1-on-1 care.

Patients with SCAD and comorbid depression had greater rates of heart failure, cerebrovascular disease, acute kidney injury, and atrial fibrillation.

Alva and Meyer offer a glimpse into what attendees can expect in the schizophrenia portion of the Southern California Psychiatry Conference.